Related Experiment Video
Updated: Jan 1, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
13.7K
Case report: Adenosquamous carcinoma of the prostate with greater than 20 month response to multimodal therapy
Alex Hennessey1, Dylan Buller2, Shashank Sama3
1Division of Urology, UConn Health, 263 Farmington Avenue, Farmington, CT, USA.
Urology Case Reports
|December 24, 2019
Abstract:
Adenosquamous carcinoma is an extremely rare and lethal subtype of prostate cancer affecting an estimated 0.03 per million men annually. It has been associated with prior hormone therapy for prostate adenocarcinoma. We present a case of de novo adenosquamous carcinoma of the prostate treated with a multimodal approach including surgery, androgen-deprivation therapy, chemotherapy, and radiation.
